What is the recommended method to transition a patient from rivaroxaban to apixaban, including dosing and timing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Switching from Rivaroxaban to Apixaban

When switching from rivaroxaban to apixaban, discontinue rivaroxaban and start apixaban at the time of the next scheduled rivaroxaban dose—no bridging or overlap is needed. 1

Switching Protocol

The FDA-approved apixaban prescribing information provides clear guidance for this transition 1:

  • Stop rivaroxaban at your regular dosing time
  • Start apixaban at the exact time you would have taken your next rivaroxaban dose
  • No gap or overlap between medications is required
  • No bridging anticoagulation (such as heparin or enoxaparin) is necessary

Appropriate Apixaban Dosing

The correct apixaban dose depends on your indication:

For Atrial Fibrillation (Stroke Prevention)

  • Standard dose: 5 mg twice daily
  • Reduced dose: 2.5 mg twice daily if you have at least 2 of the following:
    • Age ≥80 years
    • Body weight ≤60 kg
    • Serum creatinine ≥1.5 mg/dL

2, 3, 4, 1

For Venous Thromboembolism (DVT/PE Treatment)

  • Initial 7 days: 10 mg twice daily
  • After 7 days: 5 mg twice daily
  • Extended prevention (after ≥6 months): 2.5 mg twice daily

5, 1

Critical Dosing Distinction

A common and dangerous pitfall: The VTE treatment dose differs from the atrial fibrillation dose. If you're switching for VTE treatment, you must use the higher 10 mg twice daily dose initially, not the 5 mg dose used for atrial fibrillation 5. Using the wrong dose could lead to treatment failure or recurrent thrombosis.

Clinical Outcomes Evidence

Recent high-quality evidence suggests apixaban may offer advantages over rivaroxaban:

  • For VTE: The 2026 COBRRA trial (n=2,760) demonstrated apixaban had significantly lower clinically relevant bleeding compared to rivaroxaban (3.3% vs 7.1%; relative risk 0.46,95% CI 0.33-0.65, p<0.001) 6

  • For atrial fibrillation: A 2024 real-world study found that switching from apixaban to rivaroxaban increased stroke/systemic embolism risk (HR 1.99) and major bleeding risk (HR 1.80), while switching from rivaroxaban to apixaban showed similar stroke risk but lower bleeding risk (HR 0.49) 7

  • Warfarin to DOAC switching: A 2025 nationwide study showed switching from warfarin to apixaban reduced composite outcomes (rate ratio 0.92), while switching to rivaroxaban increased risk (rate ratio 1.08) 8

Timing Considerations

Important caveat: When switching between any anticoagulants, there is a transient increased risk during the first 60 days, followed by risk stabilization thereafter 8. This early transition period requires heightened vigilance for both bleeding and thrombotic complications.

Renal Function Monitoring

Both rivaroxaban and apixaban require dose adjustment for renal impairment, but the thresholds differ 4, 1:

  • Rivaroxaban: Dose reduction at CrCl 15-50 mL/min
  • Apixaban: Dose reduction based on multiple criteria (age, weight, creatinine) for atrial fibrillation; no specific renal dose adjustment for VTE treatment doses

Verify renal function before switching to ensure appropriate apixaban dosing.

Drug Interactions

If you're taking combined P-glycoprotein and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir), apixaban doses of 5 mg or 10 mg twice daily should be reduced by 50%. Avoid these inhibitors entirely if already on apixaban 2.5 mg twice daily 1.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.